X
[{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene: Positive Clinical Results for TG4001 and TG6002 and Financial Visibility Secured Until 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Transgene","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b\/2 Trial of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Transgene","sponsor":"Merck Group","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Expands Phase II Trial of TG4001 in Combination With Avelumab Vs Avelumab Monotherapy in HPV16-positive Anogenital Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Transgene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals for Tipapkinogen sovacivec
Filters
Companies By Therapeutic Area
Details:
TG4001 is a therapeutic cancer vaccine candidate using an attenuated and modified poxvirus (MVA) as a vector expressing the HPV16 E6 and E7 proteins (rendered non-oncogenic) interleukin-2.
Lead Product(s):
Tipapkinogen sovacivec ,Avelumab
Therapeutic Area: Oncology
Product Name: TG4001
Highest Development Status: IND Enabling
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 02, 2022
Details:
The initial Phase Ib/II trial conducted in Europe (France and Spain) has been amended to include a randomized comparison of the combination of TG4001 with avelumab versus avelumab monotherapy in anogenital cancers.
Lead Product(s):
Tipapkinogen sovacivec ,Avelumab
Therapeutic Area: Oncology
Product Name: TG4001
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Merck Group
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 10, 2021
Details:
Combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity with an overall response rate (ORR) of 23.5% .
Lead Product(s):
Tipapkinogen sovacivec ,Avelumab
Therapeutic Area: Oncology
Product Name: TG4001
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Merck & Co
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 09, 2020
Details:
Combination of TG4001 and avelumab demonstrates anti-tumor activity (23.5% overall response rate (ORR)) in patients with previously treated recurrent and/or metastatic HPV-related cancers.
Lead Product(s):
Tipapkinogen sovacivec ,Avelumab
Therapeutic Area: Oncology
Product Name: TG4001
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 27, 2020
Details:
The analysis of the efficacy data from the Phase 1b/2 trial combining TG4001 with avelumab in HPV16-positive recurrent and/or metastatic malignancies showed a promising clinical activity in the overall study population.
Lead Product(s):
Tipapkinogen sovacivec ,Avelumab
Therapeutic Area: Oncology
Product Name: TG4001
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Merck Group
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 16, 2020